PSKY, WBD Stocks In Focus: UK Regulator Clears Paramount Skydance's $110B Warner Bros Discovery Deal
The UK Competition and Markets Authority cleared Paramount Skydance’s proposed $110B acquisition of Warner Bros. Discovery, saying it does not risk substantially lessening competition in the U.K. and will not move to Phase 2. Paramount said approvals in 66 jurisdictions are secured. PSKY reported Q2 EPS $0.04 vs $0.17 est, revenue $6.91B. WBD reported EPS $0.06 vs -$0.1 est, revenue $8.72B vs $9.21B.
How this was made
The 30-second read
Why it matters
The CMA’s decision not to refer the deal for Phase 2 meaningfully lowers U.K. regulatory risk, but the merger remains contested in the U.S., with a scheduled March 2, 2027 trial tied to state AGs and the Writers Guild of America.
Market read
Traders can update merger-completion probabilities for both PSKY and WBD based on a concrete U.K. antitrust milestone, while still pricing in U.S. litigation and deal-integration risk.
What to watch
WBD’s revenue miss versus consensus and the absence of NBA programming in the quarter may keep fundamentals from fully catching up to deal optimism, sustaining dispersion between deal probability and operating momentum.
Background
The CMA reviewed the proposed Paramount Skydance acquisition of Warner Bros. Discovery for competition concerns across film distribution, SVOD, children’s TV, and content production/licensing.
Ticker impact
CMA cleared Paramount Skydance's proposed $110B acquisition of Warner Bros. Discovery in the U.K., reducing merger regulatory risk for PSKY.
Bias modestly positive while traders weigh clearance versus ongoing U.S. legal timeline.
The article reports a specific regulator outcome (no Phase 2) and also highlights a scheduled March 2027 trial, which can cap upside and keep volatility elevated.
Warner Bros. Discovery shares rose after the CMA cleared the $110B Paramount Skydance deal, lowering the probability of a U.K. block.
Near-term supportive, with follow-through dependent on U.S. litigation progress and integration expectations.
The CMA decision is a concrete regulatory milestone, while the article also cites a scheduled 12-day trial starting March 2, 2027, implying continued uncertainty.
Market effects
Signals continued regulatory receptiveness to large media consolidation in the U.K., potentially improving deal-completion expectations for other content-distribution combinations.
UK antitrust clearance reduces near-term probability of a U.K.-specific remedy or block for the merged media group.
The article notes similar conclusions from the European Commission and approvals across many jurisdictions, reinforcing a broader global de-risking narrative.
Counterpoint
Even with U.K. clearance, U.S. state AG and WGA litigation could still derail or materially delay the merger, limiting how much the clearance should re-rate the stocks.
Key entities
- companyParamount Skydance Corp.
U.K. regulator cleared its proposed $110B acquisition of Warner Bros. Discovery; PSKY shares were up pre-market.
- companyWarner Bros. Discovery Inc.
CMA clearance improves U.K. deal odds; WBD also reported mixed Q2 results with streaming revenue growth.
- regulatorUK Competition and Markets Authority (CMA)
Concluded the transaction does not raise a realistic prospect of substantially lessening competition in the U.K.
- courtU.S. District Judge Araceli Martínez-Olguín
Scheduled a 12-day trial beginning March 2, 2027 for lawsuits seeking to block the merger.
